KLP Kapitalforvaltning’s Sage Therapeutics SAGE Stock Holding History

KLP Kapitalforvaltning’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-9,000	Closed	-$48.9K	–	2288
2024 Q4	$48.9K	Buy	+9,000	New	+$55K	﹤0.01%	2242

Other funds holding SAGE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

KLP Kapitalforvaltning's SAGE Position: Q1 2025 in Review

KLP Kapitalforvaltning sold out of Sage Therapeutics (SAGE) in Q1 2025, closing a stake of 9,000 shares — an estimated $48.9K sold.

KLP Kapitalforvaltning first reported a position in SAGE in Q4 2024 and held it in 1 quarter. The position peaked at $48.9K in Q4 2024. 197 funds tracked by Wall St. Rank hold SAGE as of Q1 2025.

KLP Kapitalforvaltning reported no remaining Sage Therapeutics position as of Q1 2025 after selling out during the quarter.
KLP Kapitalforvaltning sold 9,000 Sage Therapeutics shares in Q1 2025, an estimated $48.9K.
KLP Kapitalforvaltning first reported a position in Sage Therapeutics in Q4 2024 and held it in 1 quarter.
KLP Kapitalforvaltning's Sage Therapeutics position peaked at $48.9K in Q4 2024.
197 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2025.

Based on KLP Kapitalforvaltning's 13F filing for Q1 2025, filed 6 May 2025.